Association between prophylactic hydrocortisone and focal intestinal perforations in preterm infants born before 28 weeks gestation: an observational propensity matched population study in England and Wales
Open Access
- 7 October 2026
- journal article
- Published by BMJ in Archives of Disease in Childhood - Fetal and Neonatal Edition
Abstract
Objective: To examine the association between prophylactic hydrocortisone, given to prevent bronchopulmonary dysplasia, and the risk of focal intestinal perforation (FIP) in preterm infants. Design: Retrospective cohort study using routinely-collected data from infants born between 2016 and 2023. Setting: All English and Welsh neonatal units. Patients: 15 746 infants born at less than 28 weeks gestation and admitted to a neonatal unit. Infants were matched (exposed vs unexposed) using a propensity score comprising 17 variables. Exposure: Exposed infants received hydrocortisone for at least eight consecutive days beginning on postnatal day one or two. Unexposed infants did not receive hydrocortisone in line with this definition. Main outcome measures: Primary outcome was FIP. Secondary outcomes included mortality, survival without FIP, bronchopulmonary dysplasia. Results: 6.3% (999/15 746) infants were exposed to early hydrocortisone and 4.6% (722/15 746) had FIP. 2815 infants (988 exposed and 1827 unexposed) were included in the matched analysis; 47% girls, median gestational age of 26.0 weeks (IQR 24.6–26.9) and median birth weight of 815 g (IQR 674–965). There was no significant difference in risk of FIP (4.9% (48/988) exposed vs 6.1% (111/1827) unexposed, OR 0.79, 95% CI 0.55 to 1.14); findings were consistent in the sensitivity analyses. Early hydrocortisone was associated with increased mortality (21.3% (210/988) exposed vs 16.2% (295/1827) unexposed, OR 1.40, 95% CI 1.14 to 1.72). Conclusions: Early prophylactic hydrocortisone from the first postnatal week was not associated with FIP. The observed association with higher mortality was a secondary finding in this observational study and requires cautious interpretation and further investigation.Keywords
Funding Information
- Imperial NIHR Biomedical Research Centre (NIHR203323)
- Imperial College London (CID: 02064746)
- National Institute for Health and Care Research (Advanced Fellowship NIHR300617)
This publication has 23 references indexed in Scilit:
- Early Prophylactic Hydrocortisone and Bronchopulmonary Dysplasia–Free Survival in Extremely Preterm InfantsJAMA Network Open, 2026
- Prophylactic hydrocortisone and the risk of sepsis in neonates born extremely pretermEuropean Journal of Pediatrics, 2025
- Prophylactic low-dose hydrocortisone in neonates born extremely preterm: current knowledge and future challengesPediatric Research, 2024
- Tolerance of hydrocortisone prophylaxis administration in extreme preterm neonates: Experience of a single UK level III neonatal unitEarly Human Development, 2022
- Mortality after 36 weeks postmenstrual age of extremely preterm infants in neonatal care: The impact of growth impairment and bronchopulmonary dysplasiaEarly Human Development, 2022
- Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): a double-blind, placebo-controlled, multicentre, randomised trialThe Lancet, 2016
- Survival and Morbidity of Preterm Children Born at 22 Through 34 Weeks’ Gestation in France in 2011JAMA Pediatrics, 2015
- Pretreatment cortisol values may predict responses to hydrocortisone administration for the prevention of bronchopulmonary dysplasia in high-risk infantsThe Journal of Pediatrics, 2005
- A Randomized-Controlled Trial of Prophylactic Hydrocortisone Supplementation for the Prevention of Hypotension in Extremely Low Birth Weight InfantsJournal of Perinatology, 2004
- Severe bronchopulmonary dysplasia increases risk for later neurological and motor sequelae in preterm survivorsDevelopmental Medicine & Child Neurology, 2000